Breaking News

Friday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Roche acquires Stratos Genomics to further develop DNA based sequencing » 06:09 05/22/20 05/22 06:09 05/22/20 06:09 RHHBY Roche $0.00 / + (+0.00%) Roche announced that it… Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche's nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion, Roche said in a statement. "Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients," said Thomas Schinecker, CEO Roche Diagnostics. "We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche." Stratos Genomics will continue operations in Seattle, Washington, U.S. Financial details of the agreement were not disclosed. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/19/20 Roche: Elecsys Anti-SARS-CoV-2 antibody test live at more than 20 U.S. sites 05/18/20 Roche announces fifth indication for Tecentriq in lung cancer approved by FDA 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories RHHBY Roche $0.00 / + (+0.00%) 05/15/20 Barclays Roche price target raised to CHF 395 from CHF 385 at Barclays 05/14/20 Mizuho Arcus Biosciences price target raised to $40 from $22 at Mizuho 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG

Over a week ago
Hot Stocks	Roche: Elecsys Anti-SARS-CoV-2 antibody test live at more than 20 U.S. sites » 16:28 05/19/20 05/19 16:28 05/19/20 16:28 RHHBY Roche $0.00 / + (+0.00%) Roche announced its… Roche announced its Elecsys(R) Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability to perform millions of tests per week. The Elecsys Anti-SARS-CoV-2 antibody test received Emergency Use Authorization from the FDA earlier this month ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/18/20 Roche announces fifth indication for Tecentriq in lung cancer approved by FDA 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization RHHBY Roche $0.00 / + (+0.00%) 05/15/20 Barclays Roche price target raised to CHF 395 from CHF 385 at Barclays 05/14/20 Mizuho Arcus Biosciences price target raised to $40 from $22 at Mizuho 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
Hot Stocks	Roche announces fifth indication for Tecentriq in lung cancer approved by FDA » 15:32 05/18/20 05/18 15:32 05/18/20 15:32 RHHBY Roche $0.00 / + (+0.00%) Genentech, a member of… Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Tecentriq as a first-line treatment for adults with metastatic non-small cell lung cancer, or NSCLC, whose tumors have high PD-L1 expression, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, said, "Today marks the fifth approval of Tecentriq in lung cancer, as we remain committed to providing an effective and tailored treatment option for every person diagnosed with this disease." In the U.S., Tecentriq has received four approvals across NSCLC, including as a single agent or in combination with targeted therapies and/or chemotherapies. It is also approved in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II RHHBY Roche $0.00 / + (+0.00%) 05/15/20 Barclays Roche price target raised to CHF 395 from CHF 385 at Barclays 05/14/20 Mizuho Arcus Biosciences price target raised to $40 from $22 at Mizuho 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 05/18/20 Global Healthcare Virtual Conference 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
Recommendations	Roche price target raised to CHF 395 from CHF 385 at Barclays » 12:59 05/15/20 05/15 12:59 05/15/20 12:59 RHHBY Roche $0.00 / + (+0.00%) Barclays analyst Emmanuel… Barclays analyst Emmanuel Papadakis raised the firm's price target on Roche to CHF 395 from CHF 385 and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Mizuho Arcus Biosciences price target raised to $40 from $22 at Mizuho 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
On The Fly	Allogene jumps, Compugen plunges following release of cancer meeting abstracts » 12:51 05/14/20 05/14 12:51 05/14/20 12:51 MEIP MEI Pharma $2.85 / +0.02 (+0.71%) , SGEN Seattle Genetics $161.66 / +3.87 (+2.45%) , EXEL Exelixis $24.93 / -1.6 (-6.03%) , MGNX MacroGenics $25.33 / -1.17 (-4.42%) , CGEN Compugen $11.20 / -2.73 (-19.60%) , INO Inovio $13.46 / +0.11 (+0.82%) , ALLO Allogene Therapeutics $40.79 / +9.8 (+31.62%) , MRK Merck $79.39 / +1.52 (+1.95%) , RHHBY Roche $0.00 / + (+0.00%) On Wednesday after market… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SGEN RHHBY MRK MGNX MEIP INO EXEL CGEN ALLO SGEN Seattle Genetics $161.66 / +3.87 (+2.45%) 05/14/20 Takeda Pharmaceutical receives EC approval for Adcetris MA extension 05/12/20 Seattle Genetics Tukysa receives Swiss Agency for Therapeutic Products approval 04/30/20 Seattle Genetics sees FY20 ADCETRIS net product sales $675M-$700M 04/17/20 Seattle Genetics enters commercial supply agreement with Sterling Pharma RHHBY Roche $0.00 / + (+0.00%) 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II MRK Merck $79.39 / +1.52 (+1.95%) 05/13/20 Merck's Keytruda superior to Brentuximab Vedotin in cHL patients in ph.3 trial 05/13/20 Merck's Keytruda demonstrates clinical benefit in stage 3 NSCLC 05/13/20 Merck's ph.2 MK-6482 study saw 28% ORR, median duration response not yet reached 05/13/20 Merck Animal Health to acquire U.S. rights to SENTINEL brands from Virbac MGNX MacroGenics $25.33 / -1.17 (-4.42%) 05/13/20 MacroGenics 'encouraged' by early demonstration activity of MGD013 05/06/20 MacroGenics trading resumes 05/06/20 MacroGenics trading halted, volatility trading pause 03/04/20 MacroGenics chief medical officer Wigginton to leave company MEIP MEI Pharma $2.85 / +0.02 (+0.71%) 05/14/20 MEI Pharma says ME-401 phase 1b study to be highlighted at EHA meeting 05/13/20 MEI Pharma, Helsinn report 'promising' data from pracinostat combo study 04/14/20 MEI Pharma and Kyowa Kirin enter into global agreement to develop ME-401 03/31/20 MEI Pharma receives FDA Fast Track designation for PI3K INO Inovio $13.46 / +0.11 (+0.82%) 05/14/20 Inovio's INO-5401 combination shows 85% survival in glioblastoma 04/30/20 Inovio expanding COVID-19 vaccine production with $1.3M CEPI grant 04/28/20 Inovio and GeneOne announces interim data from Phase 1/2a trial of INO-4700 04/28/20 Inovio completes enrollment for Phase 1 U.S. clinical trial COVID-19 vaccine EXEL Exelixis $24.93 / -1.6 (-6.03%) 05/13/20 Exelixis to present ph. 1b trial results for cabozantinib+atezolizumab as ASCO 04/20/20 Bristol-Myers, Exelixis: CheckMate-9ER met primary endpoint of PFS 03/25/20 Exelixis says Takeda Pharmaceutical receives approval in Japan for CABOMETYX 02/25/20 Fly Intel: After Hours Movers CGEN Compugen $11.20 / -2.73 (-19.60%) 04/22/20 Compugen granted patent in Europe for backup cancer antibodies 04/20/20 Compugen and Bayer's BAY 1905254 study results published in reviewed paper 04/06/20 Compugen: First patient dosed in COM902 Phase 1 trial 03/09/20 Compugen announces updated results from ongoing COM701 Phase 1 study ALLO Allogene Therapeutics $40.79 / +9.8 (+31.62%) 05/13/20 Allogene Therapeutics jumps 32% after reporting ALLO-501 data 05/06/20 Allogene Therapeutics expects 2020 net losses $260M-$280M 05/06/20 Allogene Therapeutics expects to initiate cGMP manufacturing in 2021 05/06/20 Allogene Therapeutics continues pre-clinical work on ALLO-316 MEIP SGEN EXEL MGNX CGEN INO ALLO MRK RHHBY MEIP MEI Pharma $2.85 / +0.02 (+0.71%) 04/14/20 JonesTrading MEI Pharma price target raised to $9 from $6 at JonesTrading 04/14/20 Wells Fargo MEI Pharma price target raised to $13 from $11 at Wells Fargo SGEN Seattle Genetics $161.66 / +3.87 (+2.45%) 05/01/20 Fly Intel: Top five analyst upgrades 05/01/20 Guggenheim Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential 05/01/20 H.C. Wainwright Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright 05/01/20 Guggenheim Seattle Genetics upgraded to Buy from Neutral at Guggenheim EXEL Exelixis $24.93 / -1.6 (-6.03%) 05/14/20 SunTrust Exelixis price target raised to $40 from $35 at SunTrust 05/13/20 Piper Sandler Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler 05/06/20 Piper Sandler Exelixis price target raised to $30 from $23 at Piper Sandler 04/21/20 Guggenheim Exelixis price target raised to $32 from $27 at Guggenheim MGNX MacroGenics $25.33 / -1.17 (-4.42%) 05/14/20 Wedbush MacroGenics price target raised to $28 from $16 at Wedbush 05/12/20 Credit Suisse MacroGenics price target raised to $30 from $13 at Credit Suisse 05/06/20 H.C. Wainwright MacroGenics price target raised to $22 from $18 at H.C. Wainwright 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view CGEN Compugen $11.20 / -2.73 (-19.60%) 05/13/20 Fly Intel: Top five analyst initiations 05/13/20 Stifel Compugen initiated with a Buy at Stifel 05/07/20 Fly Intel: Top five analyst initiations 05/07/20 SVB Leerink Compugen initiated with an Outperform at SVB Leerink INO Inovio $13.46 / +0.11 (+0.82%) 04/30/20 Roth Capital Inovio downgraded to Neutral from Buy at Roth Capital 04/29/20 Cantor Fitzgerald Inovio price target raised to $17 from $13 at Cantor Fitzgerald 04/29/20 H.C. Wainwright Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright 04/29/20 Stifel Stifel more than doubles Inovio target to $19, sees favorable setup ALLO Allogene Therapeutics $40.79 / +9.8 (+31.62%) 05/14/20 Oppenheimer Allogene Therapeutics price target raised to $50 from $44 at Oppenheimer 05/14/20 Jefferies Jefferies raises price target on 'ASCO winner' Allogene Therapeutics to $45 05/14/20 SunTrust Allogene Therapeutics downgraded to Hold from Buy at SunTrust 05/14/20 Stifel Durability remains a key question for Allogene's ALLO-501, says Stifel MRK Merck $79.39 / +1.52 (+1.95%) 04/27/20 SVB Leerink Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades 04/06/20 Raymond James NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James 03/23/20 Mizuho Merck business disruptions have been modest, says Mizuho 03/02/20 William Blair Merck results revive fears about Seattle Genetics' Adcetris, says William Blair RHHBY Roche $0.00 / + (+0.00%) 05/14/20 Mizuho Arcus Biosciences price target raised to $40 from $22 at Mizuho 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush SGEN RHHBY MRK MGNX MEIP INO EXEL CGEN ALLO SGEN Seattle Genetics $161.66 / +3.87 (+2.45%) 04/30/20 Seattle Genetics reports Q1 EPS (98c), consensus (79c) 02/06/20 Seattle Genetics sees 2020 Adcetris net sales $675M-$700M 02/06/20 Seattle Genetics reports Q4 EPS 14c, consensus (45c) 02/06/20 Notable companies reporting after market close RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine MRK Merck $79.39 / +1.52 (+1.95%) 04/28/20 Merck cuts FY20 EPS view to $5.17-$5.37 from $5.62-$5.77, consensus $5.56 04/28/20 Merck reports Q1 EPS $1.50, consensus $1.34 04/27/20 Notable companies reporting before tomorrow's open 04/27/20 Fly Intel: What to watch in Merck earnings report MGNX MacroGenics $25.33 / -1.17 (-4.42%) 05/05/20 MacroGenics reports Q1 EPS (91c), consensus ($1.02) MEIP MEI Pharma $2.85 / +0.02 (+0.71%) 05/07/20 MEI Pharma reports Q3 EPS (4c), consensus (14c) 02/06/20 MEI Pharma reports Q2 EPS (26c), consensus (17c) INO Inovio $13.46 / +0.11 (+0.82%) 05/11/20 Inovio reports Q1 EPS (26c), consensus (22c) 03/12/20 Inovio reports Q4 EPS (38c), consensus (24c) EXEL Exelixis $24.93 / -1.6 (-6.03%) 05/05/20 Exelixis sees FY20 revenue $850M-$900M, consensus $886.93M. 05/05/20 Exelixis reports Q1 adjusted EPS 19c, consensus 13c 02/25/20 Exelixis reports Q4 EPS 26c, consensus 16c 01/12/20 Exelixis sees FY20 revenue $850M-$900M, consensus $1B CGEN Compugen $11.20 / -2.73 (-19.60%) 05/06/20 Compugen reports Q1 EPS (10c), consensus (10c) 02/20/20 Compugen reports Q4 EPS (10c), consensus (11c) ALLO Allogene Therapeutics $40.79 / +9.8 (+31.62%) 05/06/20 Allogene Therapeutics reports Q1 EPS (50c), consensus (58c) 02/27/20 Allogene Therapeutics reports Q4 EPS (58c), consensus (68c) RHHBY MRK INO RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports MRK Merck $79.39 / +1.52 (+1.95%) 04/18/20 Pharma industry among best places to take shelter amid pandemic, Barron's says 04/09/20 Merck venture unit invests $5M in Seeqc, WSJ reports 03/28/20 Merck, Intel among stocks multifactor-screened for extra safety, Barron's says 02/01/20 Big pharma not rushing in to develop coronavirus vaccine, Barron's says INO Inovio $13.46 / +0.11 (+0.82%) 05/11/20 U.S.to accuse China of tying to steal COVID-19 intellectual property, WSJ says 04/27/20 Citron compares Inovio to Theranos, says stock heading to $1 04/13/20 Moderna, Inovio have coronavirus vaccines being tested in humans, The Print says 03/23/20 Nearly 70 drugs may be effective in treating coronavirus, NY Times reports SGEN RHHBY MRK MGNX MEIP INO EXEL ALLO SGEN Seattle Genetics $161.66 / +3.87 (+2.45%) 05/01/20 Fly Intel: Gilead, Beyond Meat downgrades among today's top calls on Wall Street 04/30/20 Fly Intel: After-Hours Movers RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines MRK Merck $79.39 / +1.52 (+1.95%) 04/28/20 Fly Intel: Wall Street's top stories for Tuesday 04/28/20 Fly Intel: Wall Street's top stories at midday 04/28/20 Fly Intel: Pre-market Movers MGNX MacroGenics $25.33 / -1.17 (-4.42%) 05/14/20 Fly Intel: Pre-market Movers 11/21/19 Fly Intel: Wall Street's top stories at midday 11/21/19 Semi equipment makers cut to sell among today's top calls MEIP MEI Pharma $2.85 / +0.02 (+0.71%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts INO Inovio $13.46 / +0.11 (+0.82%) 04/16/20 Fly Intel: Pre-market Movers 03/23/20 Fly Intel: Wall Street's top stories for Monday EXEL Exelixis $24.93 / -1.6 (-6.03%) 04/20/20 Fly Intel: Wall Street's top stories for Monday 04/20/20 Fly Intel: Wall Street's top stories at midday 04/20/20 Fly Intel: Pre-market Movers ALLO Allogene Therapeutics $40.79 / +9.8 (+31.62%) 05/13/20 Fly Intel: After-Hours Movers 12/03/19 Meet Cellectis: A Fly exclusive interview with CEO André Choulika 05/29/20 Virtual Annual Meeting of ASCO 2020 05/14/20 Seattle Genetics - SGEN 07/31/20 Merck - MRK 06/04/20 PDUFA Date for RECARBRIO 06/16/20 PDUFA Date for KEYTRUDA 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/20/20 PDUFA Date for Tucantinib 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/14/20 MacroGenics, Inc. 05/14/20 Inovio Pharmaceuticals, Inc 05/15/20 Seattle Genetics Inc. 05/20/20 Exelixis, Inc. 09:00 Today Merck & Co. Inc. 05/30/20 Roche Holding AG 06/05/20 Allogene Therapeutics, Inc. MRK MEIP INO EXEL MRK Merck $79.39 / +1.52 (+1.95%) 05/14/20 Early notable gainers among liquid option names on May 14th 04/09/20 Merck call volume above normal and directionally bullish 02/05/20 Unusually active option classes on open February 5th MEIP MEI Pharma $2.85 / +0.02 (+0.71%) 04/28/20 Unusual call flow in option market yesterday 04/27/20 MEI Pharma call buyer in opening seconds INO Inovio $13.46 / +0.11 (+0.82%) 05/11/20 Unusually active option classes on open May 11th 05/08/20 Inovio call volume above normal and directionally bullish 05/07/20 Largest borrow rate increases among liquid names 04/23/20 Unusually active option classes on open April 23rd EXEL Exelixis $24.93 / -1.6 (-6.03%) 05/11/20 Exelixis call volume above normal and directionally bullish 05/08/20 Exelixis call volume above normal and directionally bullish 03/06/20 Exelixis call volume above normal and directionally bullish 02/18/20 Exelixis put volume heavy and directionally bearish

Recommendations	Arcus Biosciences price target raised to $40 from $22 at Mizuho » 06:43 05/14/20 05/14 06:43 05/14/20 06:43 RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) , RHHBY Roche $0.00 / + (+0.00%) Mizuho analyst Mara… Mizuho analyst Mara Goldstein raised the firm's price target on Arcus Biosciences (RCUS) to $40 from $22 and keeps a Buy rating on the shares. The analyst sees Roche's (RHHBY) tiragolumab data as validation of the synergistic mechanism of the doublet of anti-TIGIT plus PD-(L)1 inhibition, which Arcus is exploring via AB154. The new price target reflects an added probability of success of 50% for AB154. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY RCUS RHHBY Roche $0.00 / + (+0.00%) 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 04/16/20 Arcus Biosciences rises 84.2% 04/16/20 Arcus Biosciences rises 21.0% 04/16/20 Arcus Biosciences trading resumes 04/16/20 Arcus Biosciences trading halted, volatility trading pause RCUS RHHBY RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 04/16/20 JonesTrading Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading 04/16/20 Cantor Fitzgerald Gilead may be entertaining acquisition of Arcus, says Cantor Fitzgerald RHHBY Roche $0.00 / + (+0.00%) 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 04/30/20 HSBC Roche upgraded to Hold from Reduce at HSBC RHHBY RCUS RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 05/05/20 Arcus Biosciences reports Q1 EPS (63c), consensus (56c) 03/05/20 Arcus Biosciences reports Q4 EPS (38c), consensus (51c) RHHBY RCUS RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 04/15/20 Gilead in talks to buy stake in Arcus Biosciences, Bloomberg says 04/15/20 Gilead in talks to buy stake in Arcus Biosciences, Bloomberg says RHHBY RCUS RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 04/16/20 Fly Intel: Wall Street's top stories for Thursday 04/16/20 Fly Intel: Wall Street's top stories at midday 04/16/20 Fly Intel: Pre-market Movers 04/15/20 Fly Intel: After-Hours Movers 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG 06/04/20 Arcus Biosciences, Inc. RCUS RCUS Arcus Biosciences $30.98 / +1.61 (+5.48%) 05/01/20 Arcus Biosciences options imply 19.7% move in share price post-earnings
Upgrade	Roche upgraded to Outperform from Peer Perform at Wolfe Research » 09:30 05/13/20 05/13 09:30 05/13/20 09:30 RHHBY Roche / + Wolfe Research analyst… Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a price target of CHF 410, up from CHF 343. While he is not changing his estimates, he has raised his multiple to reflect his view of the company's pipeline and expectation for upward revisions to the outlook. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche / + 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II RHHBY Roche / + 05/13/20 Wolfe Research Roche upgraded to Outperform from Peer Perform at Wolfe Research 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 04/30/20 HSBC Roche upgraded to Hold from Reduce at HSBC 04/28/20 UBS Roche price target raised to CHF 380 from CHF 350 at UBS RHHBY Roche / + 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche / + 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche / + 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 05/13/20 Global Metals, Mining & Steel Virtual Conference 2020 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
Upgrade	Roche upgraded to Outperform from Peer Perform at Wolfe Research » 05:48 05/13/20 05/13 05:48 05/13/20 05:48 RHHBY Roche $0.00 / + (+0.00%) Wolfe Research analyst… Wolfe Research analyst Timothy Anderson upgraded Roche to Outperform from Peer Perform with a CHF 410 price target. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/12/20 Roche announces launch of new KAPA Target Enrichment portfolio 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II RHHBY Roche $0.00 / + (+0.00%) 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 04/30/20 HSBC Roche upgraded to Hold from Reduce at HSBC 04/28/20 UBS Roche price target raised to CHF 380 from CHF 350 at UBS 04/28/20 Morgan Stanley Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
Hot Stocks	Roche announces launch of new KAPA Target Enrichment portfolio » 10:03 05/12/20 05/12 10:03 05/12/20 10:03 RHHBY Roche $0.00 / + (+0.00%) Roche announced the… Roche announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target enrichment solutions for sequencing. "KAPA HyperExome is a whole exome research panel with significantly improved performance over the existing on-market SeqCap portfolio and other products on the market. In addition to the Target Enrichment portfolio, Roche is also launching the new HyperDesign tool that enables researchers to create custom target enrichment designs that utilize the new KAPA HyperChoice probes. The probes are paired with a streamlined, automatable workflow," the company said. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 05/03/20 Fly Intel: Top five weekend stock stories 05/03/20 Roche COVID-19 antibody test receives FDA Emergency Use Authorization 04/28/20 Roche's Genentech announces new analyses of Phase III OPERA I, OPERA II 04/28/20 Roche's Genentech: FIREFISH Part 2 results met primary endpoint RHHBY Roche $0.00 / + (+0.00%) 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 04/30/20 HSBC Roche upgraded to Hold from Reduce at HSBC 04/28/20 UBS Roche price target raised to CHF 380 from CHF 350 at UBS 04/28/20 Morgan Stanley Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley RHHBY Roche $0.00 / + (+0.00%) 04/22/20 Roche confirms outlook for 2020 based on assessment of COVID-19 04/22/20 Roche reports Q1 group sales CHF 15.143B vs. CHF 14.826B last year 01/30/20 Roche reports FY19 core EPS CHF20.16 vs. CHF18.14 last year 12/02/19 Genentech says SAkuraSky data published in New England Journal of Medicine RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Roche CEO to CNBC: 'Very likely' people develop immunity after COVID-19 04/29/20 PTC and Roche trial results could be 'trouble' for Biogen's Spinraza, STAT says 03/26/20 Roche reaches deal with Britain to boost COVID-19 testing, Reuters reports 03/06/20 Roche bid to block Amgen's Herceptin biosimilar fails, Bloomberg reports RHHBY Roche $0.00 / + (+0.00%) 05/04/20 Fly Intel: Wall Street's top stories for Monday 05/04/20 Fly Intel: Wall Street's top stories at midday 03/20/20 Inovio, Moderna gain ahead of Sunday's 60 Minutes report on COVID-19 vaccines 03/18/20 COVID-19 drug seen as possible this year, vaccine in 2021 as crisis continues 05/29/20 Virtual Annual Meeting of ASCO 2020 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/30/20 Roche Holding AG
Conference/Events	Jefferies medtech analysts to hold an analyst/industry conference call » 12:25 05/08/20 05/08 12:25 05/08/20 12:25 ABT Abbott $94.20 / +0.29 (+0.31%) , BDX Becton Dickinson $256.03 / +0.2 (+0.08%) , BIO Bio-Rad $460.14 / -3.12 (-0.67%) , CPHD Cepheid $0.00 / + (+0.00%) , DGX Quest Diagnostics $111.17 / +3.8 (+3.54%) , HOLX Hologic $52.51 / -0.43 (-0.81%) , LH LabCorp $165.44 / +5.43 (+3.39%) , RHHBY Roche $0.00 / + (+0.00%) MedTech Analysts Petrone… MedTech Analysts Petrone & Denhoy, along with Key Opinion Leader Dr. Babkowski, Laboratory Medical Director at Stamford Hospital, discuss COVID-19 testing and point-of-care settings (companies of interest: ABT BDX BIO CPHD HOLX LH RHHBY) on an Analyst/Industry conference call to be held on May 8 at 1 pm. ShowHide Related Items >><< Street Research Events ABT BDX BIO CPHD DGX HOLX LH RHHBY ABT Abbott $94.20 / +0.29 (+0.31%) 04/20/20 Barclays Abbott price target raised to $100 from $92 at Barclays 04/20/20 Barclays Abbott price target raised to $100 from $92 at Barclays 04/17/20 Raymond James Abbott price target raised to $102 from $92 at Raymond James 04/17/20 Credit Suisse Abbott price target raised to $106 from $95 at Credit Suisse BDX Becton Dickinson $256.03 / +0.2 (+0.08%) 04/08/20 Wells Fargo Becton Dickinson price target lowered to $270 from $279 at Wells Fargo 03/04/20 Citi Becton Dickinson initiated with a Neutral at Citi 03/02/20 Wells Fargo Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo 02/07/20 Fly Intel: Top five analyst downgrades BIO Bio-Rad $460.14 / -3.12 (-0.67%) 04/08/20 Jefferies Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies 03/03/20 Citi Bio-Rad margin expansion story in early innings, says Citi 01/07/20 Wells Fargo Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector 01/07/20 Wells Fargo Bio-Rad initiated with an Overweight at Wells Fargo CPHD Cepheid $0.00 / + (+0.00%) DGX Quest Diagnostics $111.17 / +3.8 (+3.54%) 04/28/20 Fly Intel: Top five analyst upgrades 04/28/20 Morgan Stanley Morgan Stanley upgrades Quest Diagnostics to Overweight on COVID testing boost 04/28/20 Morgan Stanley Quest Diagnostics upgraded to Overweight from Equal Weight at Morgan Stanley 04/27/20 Fly Intel: Top five analyst upgrades HOLX Hologic $52.51 / -0.43 (-0.81%) 04/30/20 Fly Intel: Top five analyst upgrades 04/30/20 SVB Leerink Hologic upgraded to Outperform at SVB Leerink on COVID-19 testing capability 04/30/20 JPMorgan Hologic price target raised to $55 from $45 at JPMorgan 04/30/20 Needham Hologic price target raised to $60 from $52 at Needham LH LabCorp $165.44 / +5.43 (+3.39%) 04/30/20 JPMorgan LabCorp price target raised to $188 from $149 at JPMorgan 04/29/20 KeyBanc LabCorp downgraded at KeyBanc after sharp recovery in share price 04/29/20 KeyBanc LabCorp downgraded to Sector Weight from Overweight at KeyBanc RHHBY Roche $0.00 / + (+0.00%) 05/06/20 Wedbush Arcus Biosciences price target raised to $40 from $26 at Wedbush 04/30/20 HSBC Roche upgraded to Hold from Reduce at HSBC 04/28/20 UBS Roche price target raised to CHF 380 from CHF 350 at UBS 04/28/20 Morgan Stanley Roche price target raised to CHF 370 from CHF 360 at Morgan Stanley 05/08/20 Medical Technology 05/29/20 Virtual Annual Meeting of ASCO 2020 05/12/20 LabCorp - LH 06/19/20 PDUFA Date for Tecentriq (Atezolizumab) 08/24/20 PDUFA Date for Risdiplam (RG7916) 11/23/20 PDUFA Date for Xofluza 05/13/20 Laboratory Corporation of America Hldgs 05/19/20 Quest Diagnostics Incorporated 05/30/20 Roche Holding AG

On The Fly

News and insights, exclusive to thefly.com

19:58	Fly Intel: Top five weekend stock stories»
13:04	Political risks could cap Alibaba valuation near term, says Stifel»
15:42	On The Fly: Weekly technical notes for Russell 2000»
15:33	On The Fly: Weekly technical notes for S&P 500»
14:17	On The Fly: ETF fund flow highlights»

View all On The Fly Stories »

Upcoming
Events (10)

REGN ...	PDUFA Date for Dupixent
SCS	Steelcase - SCS
	10th Annual Global Financial Services Virtual Conference
	Canada Summit
	KeyBanc Capital Markets Industrials & Basic Materials Virtual Conference
KLR ...	2020 Technology, Media & Telecom Virtual Conference
MRK	Living in a COVID-19 World
RM	Regional Management
NYCB	New York Community Bancorp
ETR	Entergy

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial